Andre-Jacques Auberton-Herve

Board Director

Director

US·SEC (Form 4)

Chavant Capital Acquisition Corp.Bionik Laboratories Corp.

Total declarations

Companies

▲ Purchases (1 ops.)

—

▼ Sales (0 ops.)

—

Latest filing published 26 Dec 2023 for Chavant Capital Acquisition Corp.. Read the official filing

Insider track record

Disclosed buys

Disclosed sells

T+90 hit rate

T+90 mean return

-67.1%

Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.

Signal history

No signal scores available.

Andre-Jacques Auberton-Herve: trading record in brief

Andre-Jacques Auberton-Herve, listed as board member, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Bionik Laboratories Corp. and Mobix Labs, Inc. Over a trading history stretching from 15 July 2021 to 21 December 2023, the count stands at 7 filings.

Every open-market trade on record is a purchase: 1 purchase, and no sale. The totals exclude 1 filing filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 2 share grants and 2 option exercises. 2023 to date brings 1 purchase and no sales.

The latest filing, published on 26 December 2023, reports a share grant of €1.3M in Mobix Labs, Inc. The last purchase on record was published on 21 June 2023, which is 1,215 days ago. The median gap between a trade and its publication by SEC (Form 4) is 8 days. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.